Cargando…

Breast Cancer Drug Approvals Issued by EMA: A Review of Clinical Trials

SIMPLE SUMMARY: Considering the high incidence and mortality of breast cancer, a lot of trials evaluating new drugs for the treatment of this disease are currently ongoing. However, few drugs show a statistically and clinically significant improvement in the outcomes leading to the Competent Authori...

Descripción completa

Detalles Bibliográficos
Autores principales:	Duranti, Simona, Fabi, Alessandra, Filetti, Marco, Falcone, Rosa, Lombardi, Pasquale, Daniele, Gennaro, Franceschini, Gianluca, Carbognin, Luisa, Palazzo, Antonella, Garganese, Giorgia, Paris, Ida, Scambia, Giovanni, Pietragalla, Antonella
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533780/ https://www.ncbi.nlm.nih.gov/pubmed/34680350 http://dx.doi.org/10.3390/cancers13205198

Ejemplares similares

Oncologic Drugs Approval in Europe for Solid Tumors: Overview of the Last 6 Years
por: Falcone, Rosa, et al.
Publicado: (2022)

Oligometastatic Breast Cancer: How to Manage It?
por: Barberi, Vittoria, et al.
Publicado: (2021)

Molecular Profile and Matched Targeted Therapy for Advanced Breast Cancer Patients
por: Falcone, Rosa, et al.
Publicado: (2023)

Adjuvant Treatment Recommendations in Early-Stage Endometrial Cancer: What Changes With the Introduction of The Integrated Molecular-Based Risk Assessment
por: Nero, Camilla, et al.
Publicado: (2021)

Role of Immune Checkpoint Inhibitors in Cervical Cancer: From Preclinical to Clinical Data
por: Duranti, Simona, et al.
Publicado: (2021)

Overview of Trop-2 in Cancer: From Pre-Clinical Studies to Future Directions in Clinical Settings
por: Lombardi, Pasquale, et al.
Publicado: (2023)

Ovarian Cancer Treatments Strategy: Focus on PARP Inhibitors and Immune Check Point Inhibitors
por: Nero, Camilla, et al.
Publicado: (2021)

Ovarian Reserve after Chemotherapy in Breast Cancer: A Systematic Review and Meta-Analysis
por: Romito, Alessia, et al.
Publicado: (2021)

PI3K Inhibitors in Advanced Breast Cancer: The Past, The Present, New Challenges and Future Perspectives
por: Fuso, Paola, et al.
Publicado: (2022)

Clinical and mutational profile of AT-rich interaction domain 1A-mutated cancers
por: Falcone, Rosa, et al.
Publicado: (2023)

Prospective Study Investigating the Efficacy and Safety of a Scalp Cooling Device for the Prevention of Alopecia in Women Undergoing (Neo)Adjuvant Chemotherapy for Breast Cancer
por: Carbognin, Luisa, et al.
Publicado: (2022)

The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA
por: Gherghescu, Ioana, et al.
Publicado: (2020)

Futibatinib: second EMA approval for FGFR inhibitor in cholangiocarcinoma
por: Lamarca, A., et al.
Publicado: (2023)

Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999–2014
por: Hatswell, Anthony J, et al.
Publicado: (2016)

Conservative Surgery in cT4 Breast Cancer: Single-Center Experience in the Neoadjuvant Setting
por: Franco, Antonio, et al.
Publicado: (2023)

Integration of PARP-inhibitors in ovarian cancer therapy
por: Pietragalla, Antonella, et al.
Publicado: (2020)

Development of a nomogram for predicting pathological complete response in luminal breast cancer patients following neoadjuvant chemotherapy
por: Garufi, Giovanna, et al.
Publicado: (2023)

EMA issues recommendations on impurities in medicines
Publicado: (2020)

BRCA Mutation Status in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Pivotal Role for Treatment Decision-Making
por: Pavese, Francesco, et al.
Publicado: (2022)

PTEN and Gynecological Cancers
por: Nero, Camilla, et al.
Publicado: (2019)

Detection of Toxocara cati Larvae in a Common Buzzard (Buteo buteo) and in a Red Kite (Milvus milvus) in Basilicata Region, Italy
por: Toce, Mariateresa, et al.
Publicado: (2022)

Assessing the pathogenicity of BRCA1/2 variants of unknown significance: Relevance and challenges for breast cancer precision medicine
por: De Paolis, Elisa, et al.
Publicado: (2023)

Lutathera(®): The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy
por: Hennrich, Ute, et al.
Publicado: (2019)

Extension of the European Medicines Agency (EMA) approval of trifluridine/tipiracil for gastric cancer
por: Alsina, Maria, et al.
Publicado: (2019)

Rethinking treatment for RET-altered lung and thyroid cancers: selpercatinib approval by the EMA
por: Della Corte, C.M., et al.
Publicado: (2021)

Updated Neoadjuvant Treatment Landscape for Early Triple Negative Breast Cancer: Immunotherapy, Potential Predictive Biomarkers, and Novel Agents
por: Garufi, Giovanna, et al.
Publicado: (2022)

Expanded Access as a source of real‐world data: An overview of FDA and EMA approvals
por: Polak, Tobias B., et al.
Publicado: (2020)

Overview of the Side-Effects of FDA- and/or EMA-Approved Targeted Therapies for the Treatment of Hematological Malignancies
por: Constantinescu, Catalin, et al.
Publicado: (2020)

FDA and EMA Approvals of New Breast Cancer Drugs—A Comparative Regulatory Analysis
por: Leo, Chandra P., et al.
Publicado: (2020)

Immunotherapy in gynecological cancers
por: Lorusso, Domenica, et al.
Publicado: (2021)

Entrectinib approval by EMA reinforces options for ROS1 and tumour agnostic NTRK targeted cancer therapies
por: Ardini, Elena, et al.
Publicado: (2020)

Scaffold Searching of FDA and EMA-Approved Drugs Identifies Lead Candidates for Drug Repurposing in Alzheimer’s Disease
por: Shityakov, Sergey, et al.
Publicado: (2021)

Tucatinib approval by EMA expands options for HER2-positive locally advanced or metastatic breast cancer
por: Corti, C., et al.
Publicado: (2021)

Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA
por: Michaeli, Daniel Tobias, et al.
Publicado: (2022)

Palbociclib Plus Fulvestrant or Everolimus Plus Exemestane for Pretreated Advanced Breast Cancer with Lobular Histotype in ER+/HER2− Patients: A Propensity Score-Matched Analysis of a Multicenter Retrospective Patient Series †
por: Orlandi, Armando, et al.
Publicado: (2020)

Technology forecast: advanced therapies in late clinical research, EMA approval or clinical application via hospital exemption
por: Eder, Claudia, et al.
Publicado: (2019)

Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study
por: Hwang, Thomas J, et al.
Publicado: (2020)

Death after the Administration of COVID-19 Vaccines Approved by EMA: Has a Causal Relationship Been Demonstrated?
por: Maiese, Aniello, et al.
Publicado: (2022)

EMA : escala multidimensional de asertividad : manual /
por: Flores Galaz, Mirta Margarita
Publicado: (2004)

Ema, la cautiva
por: Aira, César, 1949-

Cannot write session to /tmp/vufind_sessions/sess_iuvbu68l5i32rietg8kel8rb21